Gandhinagar: Union Minister for Health and Family Welfare J.P. Nadda addresses at the 43rd Annual National Conference of Preventive and Social Medicine (IAPSMCON 2016), at Gandhinagar, in Gujarat on Jan 7, 2016. (Photo: IANS/PIB)
India has reversed course and granted approval to Gilead Sciences Inc`spatent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable copies of the drug.
The drug, which has a list price of $1,000 a pill in the United States, was rejected for a patent by the Indian patent authority in January 2015 on the basis it represented only minor changes to a previous formulation, and the company already had licensing deals with manufacturers in India.
After an appeal by Gilead, the Indian Patent Office of New Delhi on Monday approved its application for the drug saying it found its compounds to be "novel" and "inventive."
Gilead, in a statement, welcomed the move, but said it will have no impact on availability of the compound, which is already licensed to 11 generic manufacturers in India for distribution in 101 developing countries.
Patents guarantee drugmakers exclusive sales for a decade or more, before generic competition is allowed, so the companies can recoup their investment and use profits to then develop new medicines.
Gilead said the goal of its voluntary licensing programme, and "partnership" with Indian manufacturers, is to enable access to medicines for as many people as possible, as quickly as possible.
But patient groups said Gilead`s licensing deals do not serve patients and the patent approval could prevent exports of raw materials to other countries seeking to make the drug, hailed by some as a breakthrough in the global fight against hepatitis.
"Like unmerited patents, these schemes manipulate the market, violate patients` rights and block millions of people from getting the medicines they need," the Initiative for Medicines, Access & Knowledge said in a statement.
Gilead said eight of its licensees have launched sales in India and other licensed territories under the company`s programme for supplying its hepatitis C, hepatitis B and HIV drugs to "resource-challenged countries." Licenses have also been granted to two manufacturers in Egypt and one in Pakistan.
Sovaldi was first launched in the United States in 2013 at a list price of $28,000 for a 28-tablet bottle, or $1,000 a pill.
The list price in India as of April 26, according to the Asia Pacific Network of People Living with HIV, was $384 per bottle, or about $14 per pill.
The liver-destroying hepatitis C virus infects as many as 150 million people globally, according to the World Health Organization.
By continuing to browse or use our sites, you agree that we can store and access cookies and other tracking technologies as described in this policy.
A cookie is a small text file that can be stored on and accessed from your device when you visit one of our sites, to the extent you agree. The other tracking technologies work similarly to cookies and place small data files on your devices or monitor your website activity to enable us to collect information about how you use our sites. This allows our sites to recognize your device from those of other users on our sites. The information provided below about cookies also applies to these other tracking technologies.
These are those cookies that belong to us and which we place on your device or are those set by a website that is being visited by the user at the time (e.g., cookies placed by zeenews.india.com)
Some features used on this website may involve a cookie being sent to your computer by a third party. For example, if you view or listen to any embedded audio or video content you may be sent cookies from the site where the embedded content is hosted. Likewise, if you share any content on this website through social networks (for example by clicking a Facebook “like” button or a “Tweet” button) you may be sent cookies from these websites. We do not control the setting of these cookies so please check the websites of these third parties for more information about their cookies and how to manage them.
Session cookies are temporary and deleted from your machine when your web browser closes. We use session cookies to help us track internet usage as described above.
The data collected by the sites and/or through Cookies that may be placed on your computer will not be kept for longer than is necessary to fulfil the purposes mentioned above. In any event, such information will be kept in our database until we get explicit consent from you to remove all the stored cookies.
These cookie are essential to our site in order to enable you to move around it and to use its features. Without these essential cookies we may not be able to provide certain services or features and our site will not perform as smoothly for you as we would like. These cookies, for example, let us recognize that you have created an account and have logged in/out to access site content. They also include Cookies that enable us to remember your previous actions within the same browsing session and secure our sites.
These cookies are used by us or by our third-party service providers to analyse how the sites are used and how they are performing. For example, these cookies track what content are most frequently visited, your viewing history and from what locations our visitors come from. If you subscribe to a newsletter or otherwise register with the Sites, these cookies may be correlated to you.
These cookies let us operate the sites in accordance with the choices you make. These cookies permit us to "remember you” in-between visits. For instance, we will recognize your user name and remember how you customized the sites and services, for example by adjusting text size, fonts, languages and other parts of web pages that are alterable, and provide you with the same customizations during future visits.
If you do not want cookies to be dropped on your device, you can adjust the setting of your Internet browser to reject the setting of all or some cookies and to alert you when a cookie is placed on your device. For further information about how to do so, please refer to your browser ‘help’ / ‘tool’ or ‘edit’ section for cookie settings w.r.t your browser that may be Google Chrome, Safari, Mozilla Firefox etc.
Please note that if your browser setting is already setup to block all cookies (including strictly necessary Cookies) you may not be able to access or use all or parts or functionalities of our sites.
If you want to remove previously-stored cookies, you can manually delete the cookies at any time from your browser settings. However, this will not prevent the sites from placing further cookies on your device unless and until you adjust your Internet browser setting as described above.
For more information on the development of user-profiles and the use of targeting/advertising Cookies, please see www.youronlinechoices.eu if you are located in Europe or www.aboutads.info/choices if in the United States.